Accelerating antiviral drug discovery: lessons from COVID-19
During the coronavirus disease 2019 (COVID-19) pandemic, a wave of rapid and collaborative drug discovery efforts took place in academia and industry, culminating in several therapeutics being discovered, approved and deployed in a 2-year time frame. This article summarizes the collective experience...
| Автори: | , , , , , , , |
|---|---|
| Формат: | Journal article |
| Мова: | English |
| Опубліковано: |
Springer Nature
2023
|
| _version_ | 1826311938633629696 |
|---|---|
| author | von Delft, A Hall, MD Kwong, AD Purcell, LA Saikatendu, KS Schmitz, U Tallarico, JA Lee, AA |
| author_facet | von Delft, A Hall, MD Kwong, AD Purcell, LA Saikatendu, KS Schmitz, U Tallarico, JA Lee, AA |
| author_sort | von Delft, A |
| collection | OXFORD |
| description | During the coronavirus disease 2019 (COVID-19) pandemic, a wave of rapid and collaborative drug discovery efforts took place in academia and industry, culminating in several therapeutics being discovered, approved and deployed in a 2-year time frame. This article summarizes the collective experience of several pharmaceutical companies and academic collaborations that were active in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antiviral discovery. We outline our opinions and experiences on key stages in the small-molecule drug discovery process: target selection, medicinal chemistry, antiviral assays, animal efficacy and attempts to pre-empt resistance. We propose strategies that could accelerate future efforts and argue that a key bottleneck is the lack of quality chemical probes around understudied viral targets, which would serve as a starting point for drug discovery. Considering the small size of the viral proteome, comprehensively building an arsenal of probes for proteins in viruses of pandemic concern is a worthwhile and tractable challenge for the community. |
| first_indexed | 2024-03-07T08:18:41Z |
| format | Journal article |
| id | oxford-uuid:69dd8d38-b2d1-4f5e-a84d-07c23c581f91 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T08:18:41Z |
| publishDate | 2023 |
| publisher | Springer Nature |
| record_format | dspace |
| spelling | oxford-uuid:69dd8d38-b2d1-4f5e-a84d-07c23c581f912024-01-18T10:47:34ZAccelerating antiviral drug discovery: lessons from COVID-19Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:69dd8d38-b2d1-4f5e-a84d-07c23c581f91EnglishSymplectic ElementsSpringer Nature2023von Delft, AHall, MDKwong, ADPurcell, LASaikatendu, KSSchmitz, UTallarico, JALee, AADuring the coronavirus disease 2019 (COVID-19) pandemic, a wave of rapid and collaborative drug discovery efforts took place in academia and industry, culminating in several therapeutics being discovered, approved and deployed in a 2-year time frame. This article summarizes the collective experience of several pharmaceutical companies and academic collaborations that were active in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antiviral discovery. We outline our opinions and experiences on key stages in the small-molecule drug discovery process: target selection, medicinal chemistry, antiviral assays, animal efficacy and attempts to pre-empt resistance. We propose strategies that could accelerate future efforts and argue that a key bottleneck is the lack of quality chemical probes around understudied viral targets, which would serve as a starting point for drug discovery. Considering the small size of the viral proteome, comprehensively building an arsenal of probes for proteins in viruses of pandemic concern is a worthwhile and tractable challenge for the community. |
| spellingShingle | von Delft, A Hall, MD Kwong, AD Purcell, LA Saikatendu, KS Schmitz, U Tallarico, JA Lee, AA Accelerating antiviral drug discovery: lessons from COVID-19 |
| title | Accelerating antiviral drug discovery: lessons from COVID-19 |
| title_full | Accelerating antiviral drug discovery: lessons from COVID-19 |
| title_fullStr | Accelerating antiviral drug discovery: lessons from COVID-19 |
| title_full_unstemmed | Accelerating antiviral drug discovery: lessons from COVID-19 |
| title_short | Accelerating antiviral drug discovery: lessons from COVID-19 |
| title_sort | accelerating antiviral drug discovery lessons from covid 19 |
| work_keys_str_mv | AT vondelfta acceleratingantiviraldrugdiscoverylessonsfromcovid19 AT hallmd acceleratingantiviraldrugdiscoverylessonsfromcovid19 AT kwongad acceleratingantiviraldrugdiscoverylessonsfromcovid19 AT purcellla acceleratingantiviraldrugdiscoverylessonsfromcovid19 AT saikatenduks acceleratingantiviraldrugdiscoverylessonsfromcovid19 AT schmitzu acceleratingantiviraldrugdiscoverylessonsfromcovid19 AT tallaricoja acceleratingantiviraldrugdiscoverylessonsfromcovid19 AT leeaa acceleratingantiviraldrugdiscoverylessonsfromcovid19 |